Therapeutic potentials and challenges of cytostatic persister cancer cells
Oncotarget. 2023 Dec 1;14:944-945. doi: 10.18632/oncotarget.28488.NO ABSTRACTPMID:38039406 | PMC:PMC10691818 | DOI:10.18632/oncotarget.28488 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Paul Y Kim Cheuk T Leung Source Type: research

Osteopontin induces mitochondrial biogenesis in deadherent cancer cells
This study confirms a functional connection between the short-term oxidative metabolism and the longer-term mitochondrial biogenesis in cancer metastasis - both are induced by Osteopontin-c. The results imply possible mechanisms and targets for treating cancer metastasis.PMID:38039408 | PMC:PMC10691814 | DOI:10.18632/oncotarget.28540 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Gulimirerouzi Fnu Georg F Weber Source Type: research

Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia
Oncotarget. 2023 Dec 1;14:947-948. doi: 10.18632/oncotarget.28474.NO ABSTRACTPMID:38039409 | PMC:PMC10691817 | DOI:10.18632/oncotarget.28474 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Alessia Roma Lawrence D Goodridge Paul A Spagnuolo Source Type: research

Addendum: Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review
Oncotarget. 2023 Dec 1;14:946. doi: 10.18632/oncotarget.28285.NO ABSTRACTPMID:38039411 | PMC:PMC10691816 | DOI:10.18632/oncotarget.28285 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Hai Zou Ke-Hua Pan Liang Wu Hong-Ying Pan Ya-Hui Ding Ming-Hua Zheng Source Type: research

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
Oncotarget. 2023 Dec 1;14:949-956. doi: 10.18632/oncotarget.28538.ABSTRACTIn myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall response rates in heavily pretreated patients but progression-free survival data are poor. As the drug induces apoptosis, we hypothesized that sBCMA includes extracellular vesicles (EV) and thus evaluated numbers of BCMA-EV before and during belantamab therapy in 10 myeloma patients. BCMA-EV were significantly higher in patients prior to Belantamab (median: 3227/μl; ...
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Carsten Springer J ürgen Krauter Arne Trummer Source Type: research

Risk factors for long-term arm morbidities following breast cancer treatments: A systematic review
CONCLUSIONS: The main risk factors for long-term morbidity are removal of lymph nodes from the axilla, body mass index >30, having undergone a mastectomy, the stage of the disease, radiation therapy, chemotherapy, infection and trauma to the affected arm after surgery. An understanding of the risk factors for prolonged arm morbidity after surgery can help doctors and therapists in making personalized decisions about the need and timing of rehabilitation treatments.PMID:38039404 | PMC:PMC10691815 | DOI:10.18632/oncotarget.28539 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Ifat Klein Michael Friger Merav Ben David Danit Shahar Source Type: research

Retraction: Matrine alleviates lipopolysaccharide-induced intestinal inflammation and oxidative stress via CCR7 signal
Oncotarget. 2023 Dec 1;14:943. doi: 10.18632/oncotarget.28119.NO ABSTRACTPMID:38039405 | PMC:PMC10691811 | DOI:10.18632/oncotarget.28119 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Guojun Wu Wenhong Zhou Junfeng Zhao Xiaohua Pan Yongjie Sun Hao Xu Peng Shi Chong Geng Ling Gao Xingsong Tian Source Type: research

Therapeutic potentials and challenges of cytostatic persister cancer cells
Oncotarget. 2023 Dec 1;14:944-945. doi: 10.18632/oncotarget.28488.NO ABSTRACTPMID:38039406 | PMC:PMC10691818 | DOI:10.18632/oncotarget.28488 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Paul Y Kim Cheuk T Leung Source Type: research

Osteopontin induces mitochondrial biogenesis in deadherent cancer cells
This study confirms a functional connection between the short-term oxidative metabolism and the longer-term mitochondrial biogenesis in cancer metastasis - both are induced by Osteopontin-c. The results imply possible mechanisms and targets for treating cancer metastasis.PMID:38039408 | PMC:PMC10691814 | DOI:10.18632/oncotarget.28540 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Gulimirerouzi Fnu Georg F Weber Source Type: research

Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia
Oncotarget. 2023 Dec 1;14:947-948. doi: 10.18632/oncotarget.28474.NO ABSTRACTPMID:38039409 | PMC:PMC10691817 | DOI:10.18632/oncotarget.28474 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Alessia Roma Lawrence D Goodridge Paul A Spagnuolo Source Type: research

Addendum: Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review
Oncotarget. 2023 Dec 1;14:946. doi: 10.18632/oncotarget.28285.NO ABSTRACTPMID:38039411 | PMC:PMC10691816 | DOI:10.18632/oncotarget.28285 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Hai Zou Ke-Hua Pan Liang Wu Hong-Ying Pan Ya-Hui Ding Ming-Hua Zheng Source Type: research

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
Oncotarget. 2023 Dec 1;14:949-956. doi: 10.18632/oncotarget.28538.ABSTRACTIn myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall response rates in heavily pretreated patients but progression-free survival data are poor. As the drug induces apoptosis, we hypothesized that sBCMA includes extracellular vesicles (EV) and thus evaluated numbers of BCMA-EV before and during belantamab therapy in 10 myeloma patients. BCMA-EV were significantly higher in patients prior to Belantamab (median: 3227/μl; ...
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Carsten Springer J ürgen Krauter Arne Trummer Source Type: research

Risk factors for long-term arm morbidities following breast cancer treatments: A systematic review
CONCLUSIONS: The main risk factors for long-term morbidity are removal of lymph nodes from the axilla, body mass index >30, having undergone a mastectomy, the stage of the disease, radiation therapy, chemotherapy, infection and trauma to the affected arm after surgery. An understanding of the risk factors for prolonged arm morbidity after surgery can help doctors and therapists in making personalized decisions about the need and timing of rehabilitation treatments.PMID:38039404 | PMC:PMC10691815 | DOI:10.18632/oncotarget.28539 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Ifat Klein Michael Friger Merav Ben David Danit Shahar Source Type: research

Retraction: Matrine alleviates lipopolysaccharide-induced intestinal inflammation and oxidative stress via CCR7 signal
Oncotarget. 2023 Dec 1;14:943. doi: 10.18632/oncotarget.28119.NO ABSTRACTPMID:38039405 | PMC:PMC10691811 | DOI:10.18632/oncotarget.28119 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Guojun Wu Wenhong Zhou Junfeng Zhao Xiaohua Pan Yongjie Sun Hao Xu Peng Shi Chong Geng Ling Gao Xingsong Tian Source Type: research

Therapeutic potentials and challenges of cytostatic persister cancer cells
Oncotarget. 2023 Dec 1;14:944-945. doi: 10.18632/oncotarget.28488.NO ABSTRACTPMID:38039406 | PMC:PMC10691818 | DOI:10.18632/oncotarget.28488 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Paul Y Kim Cheuk T Leung Source Type: research